Oscar Robinson

Since joining Kirkland, Oscar has been involved in the following matters:

• Lenovo v. Ericsson — Representing Lenovo in its implementer led case for a FRAND cross licence involving multiple novel issues of law including the availability of an interim licensing regime and the availability of interim injunctive relief.
  
• Lenovo v. Ericsson — Representing Lenovo in its case for determination of provisions of the prior licence agreement existing between Ericsson and Motorola Mobility.
• InterDigital v. Lenovo — Representing Lenovo in SEP/FRAND litigation against major non-practising entity InterDigital, securing major win on FRAND rate in the second ever trial in the UK to determine global FRAND licensing terms. Also representing Lenovo in a technical trial concerning data scheduling in the LTE-Advanced standard. 
• Dr Reddy's & Ors v. Pfizer — Acting for Pfizer in damages proceedings against the Department of Health and seven Generic groups in relation to Lyrica® (pregabalin) the most complex damages inquiry considered by the UK court.
• Pfizer v. Amgen — Representing Pfizer in relation to UK patent litigation to clear the way for the launch of a major new bispecific antibody cancer treatment.
• Sisvel & Mitsubishi v. Xiaomi & Ors — Represented Xiaomi in defence of UK claims for SEP infringement and FRAND relief by Sisvel.
• Advised leading healthcare and medical device company in relation to major multinational medical device patent litigation.

Prior to joining Kirkland, Oscar was involved in the following matters:

• Unwired Planet v. Huawei / Conversant v. Huawei — Acted for Huawei in the market defining jurisdictional challenge to the UK Supreme Court made against the English Court’s ability to grant global FRAND licences.
• Conversant v. Huawei — Representing Huawei in defending a market-leading global FRAND and SEP infringement action, which settled shortly before trial. 
• Premaitha Health v. Illumina — Represented Premaitha Health, a small UK-based innovative diagnostics company, in a large, multi-patent litigation relating to non-invasive prenatal testing and next generation sequencing technology against Illumina, Inc.
• Warner-Lambert v. Actavis; Warner-Lambert v. Mylan — Represented Warner-Lambert (a Pfizer group company) in its appeal to the UK Supreme Court in relation to landmark UK second medical use patent litigation against multiple generic parties concerning Lyrica® (pregabalin), its multi-billion dollar blockbuster treatment for pain. The case is considered to be seminal authority on a wide range of previously unresolved legal issues in relation to the validity and enforcement of second medical use patents in the UK.
• Teva v. Boehringer Ingelheim — Acted for Boehringer Ingelheim in its global formulation patent against Teva in relation to BI’s blockbuster SPIRIVA® COPD inhalation product worth over $3 billion in sales worldwide.
• Warner-Lambert v. Sandoz — Represented Warner-Lambert (a Pfizer group company) in successfully securing urgent injunctive relief to prevent the launch of a full label generic version of Lyrica® (pregabalin), its multi-billion dollar blockbuster treatment for pain.
• Regeneron v. Kymab — Acted for Regeneron in its infringement claim against the Kymab Kymouse ® a case which is now a key authority on insufficiency as a result of enablement across the breadth of the claim.
• Acted for a global pharmaceutical company on worldwide product lifecycle management strategy for a key neurology product.

Allen & Overy LLP, London

• Associate, 2016–2021
• Trainee Solicitor, 2014–2016